While smart companies consider the final packaging of their product concurrently with the development of the product, sometimes it’s evident that even the smartest companies fail to consider every aspect of their packaging when it finally comes in contact with the consumer.
Harold Ramis, one of the great comedic geniuses of my generation and arguably one of the...
When I was a kid – a long, long time ago – you either took your medicine or died. At least that’...
Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?
The current buzz-term “Big Data” may be slightly misleading in the strictest sense. The concept is nothing new. Most manufacturers are quite accustomed to having “big,” some might say huge, amounts of data flowing throughout their organizations, but have historically lacked the context that gives that data actionable meaning—giving birth to the oft used phrase, “data rich, but information poor.”
The controversy over vaccinations is back in the spotlight, after a Colorado bill passed tightening the loophole that allows parents to choose not to vaccinate, and actress Kristen Cavalarri spoke out against vaccinations claiming a connection with autism. What's more frightening is the frequency of outbreaks of diseases we thought we'd eradicated.
In the past I have railed against misinformation on the web and those who use this misinformation to support their beliefs. In particular I have spoken at length about the misinformation concerning vaccinations – that there has been no credible evidence – ever – that vaccination cause any type of permanent maladies or side effects. And yet – people still think vaccines are evil and should be avoided.
Serialization and traceability can be powerful tools to combat drug counterfeiting and the pharmaceutical grey market. This is hardly a new concept, and many voices have been raised in their favor. But not all players in the pharmaceutical industry have rushed to implement them.
What do Maslow's hierarchy of needs and pharma have in common? On the surface, it might seem they have nothing in common. However, there are many points of connection in today's global economic landscape where the world has not only flattened but also shrunk.
Recently, I was listening to a radio news broadcast discussing the 50th anniversary of the first salvo in the war against cigarettes and the efforts to reduce deaths from lung cancer. I heard a commentator say that lung cancer is still the most lethal form of cancer in America. I was curious as to why they chose the term “lethal”.
The human race has one significant weakness. We all want to know what the future holds for us, and we want to know now -- hence the popularity of fortune-telling and such "fields" as astrology. In our desire to predict tomorrow, however, we often forget simple cause and effect.
Whether it’s for internal comparisons, or for measuring the effectiveness of your company against close competitors, benchmarking is a vital continuous improvement tool. And although it’s safe to say that the average executive understands the benefits of benchmarking performance, that doesn’t necessarily mean his or her company has ever participated in such an initiative.
Numbers have different meanings in different contexts or scenarios. In pharmaceuticals, a billion, or billions, in sales would define a blockbuster, while anything less than that would be seen as a marginal success, or even a failure. However, in the generics world, millions represent a sizeable business opportunity.
This past summer, when news of regulatory noncompliance troubles in the region reached a high point, I asked Indian pharma CEOs in a post on this site whether they had lost their chance to innovate.
I’m the guy who looks down his nose at every new health trend and scoffs at those who embark on low-carb diets or overindulging on pomegranates or chugging wheat grass juice or slathering their hands with anti-bacterial soap, or downing multi-vitamins and supplements like Halloween candy.
There’s a great commercial on television in which one person asks another, “Where did you read that?” and the questioned person responds, “On the internet. They can’t put anything on the internet that isn’t true.” That simple exchange typifies what I’m seeing as a growing trend – if you have a point of view, and you need some sort of citation, footnote, or endorsement for your position – just look to the internet and you can find it.
Who are the technical innovators in the US? The image we often have is that of the young Silicon Valley geek or the surfing California biopharma scientist -- sometimes brash and unafraid to challenge authority and champion new and better ideas.
Biosimilars have received a lot of attention and “buzz” lately. And, as the FDA continues to hold meetings and put out documents for comment as it decides just how to eventually approve and regulate these biopharm generics there is one question that needs to be addressed.